Info
🌱 來自: cancer pharmacology
Small Molecule Pathway Inhibitors
- Abemaciclib
- Acalabrutinib
- Afatinib
- Alectinib
- Alpelisib
- Avapritinib
- Axitinib
- Bosutinib
- Binimetinib
- Brigatinib
- Capmatinib
- Cabozantinib
- Ceritinib
- Cobimetinib
- Copanlisib
- Crizotinib
- Erdafitinib
- Erlotinib
- Dabrafenib
- Dacomitinib
- Dasatinib
- Duvelisib
- Enasidenib
- Encorafenib
- Entrectinib
- Gefitinib
- Gilteritinib
- Glasdegib
- Ibrutinib
- Idelalisib
- Imatinib
- Ivosidenib
- Lapatinib
- Larorectinib
- Lenvatinib
- Lorlatinib
- Midostaurin
- Neratinib
- Nilotinib
- Niraparib
- Olaparib
- Osimertinib
- Palbociclib
- Pazopanib
- Pexidartinib
- Ponatinib
- Regorafenib
- Ribociclib
- Ripretinib
- Rucaparib
- Ruxolitinib
- Selinexor
- Selpercatinib
- Sorafenib
- Sunitinib
- Sonidegib
- Talazoparib
- Tepotinib
- Trametinib
- Tivozanib
- Umbralisib
- Vandetanib
- Vemurafenib
- Venetoclax
- Vismodegib
- Zanubrutinib